Novartis...8ª en THE MOST CREATIVE.

NOVARTIS ocupa la posición 8ª.

Es la única compañía de las "Big Pharma" en el ranking.

Since focusing its R&D on rare diseases and biotech, including vaccines for the likes of H1N1, the Swiss pharma giant has been in a fever of invention. The FDA has approved nine of its drug candidates in 2009 alone. Chairman Daniel Vasella explains how the world's third-largest drugmaker got so healthy:

"If you're thinking along traditional lines, when a drug doesn't promise profitability and market size and growth, it will not enter the portfolio. But if we have a possibility to significantly improve the lives of patients who cannot be well treated, we'll go ahead, irrespective of the size of the market."

Después de este "bla, bla, bla..." vayamos a declaraciones menos...
(Es mejor no...?)
Aunque...mas de lo mismo.

You've described the Novartis campus in Basel, designed by Frank Gehry and other luminaries, almost as a competitive advantage. How so?

We transformed a former industrial production site into a space for knowledge workers. We abolished walls and cubicles, and we created the lab of the future, where we're integrating informatics and bioinformatics and communication tools that enhance research. If you're in the lab here in Basel, without taking off your glove, you push a button and talk to a colleague in the United States and exchange structures and talk about them. It creates a research network that spans large geographies.

You had tuberculosis and meningitis as a child, and a sister died at 19 of Hodgkin's lymphoma. How do these experiences and having been a physician influence the way you've run the company?

The clinical experience -- the touch, smell, and memory, the empathy for the patients -- remains very important. To have experienced that and also to have been sick and to have lost someone helps. You see your limitations. You think you can cure a patient, and he dies. You think a patient will die, and he gets cured. You learn that things happen that are out of your control.

Ver...